India’s ₹10,000 crore Biopharma SHAKTI scheme marks a definitive shift from low-cost generics to high-value biologics, aiming ...

In this video from the Macula Society meeting, Sunir J. Garg, MD, FACS, FASRS, discusses research concerning the development ...

With CDSCO restricting vaccine and biologic testing to government labs, experts weigh the benefits of rigorous control ...

Biocon Limited has announced the commercial launch of its denosumab biosimilars, Bosaya and Aukelso, in the United States, ...

Get all latest & breaking news on Bharti Hexacom. Watch videos, top stories and articles on Bharti Hexacom at moneycontrol.com.

As foundational AI models muscle into biosciences and pharmaceuticals, what does it mean for India's $55-billion ...

With insulin scale, US launches, GLP-1 ambitions and an oncology pipeline, the company is building where others are not looking.

Kiran Mazumdar Shaw has a number in her head: one in five. That is the share of global insulin users she wants to use a ...

Biggest opportunity lies in building global scale facilities as cos tap PLI, RDI incentives: Kiran Mazumdar-Shaw: Nandita Vijayasimha, Bengaluru Wednesday, April 8, 2026, 08:00 Hr ...

Bosaya(TM) and Aukelso(TM) (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designation -- Potential benefit to ...

Neptune grass is generally regarded as the most ecologically important seagrass and shallow-water habitat in the ...

Biocon, a biopharma giant, is escalating its artificial intelligence adoption across all operations to expedite drug ...